Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HM1.24-ETA'
- Development stage
- Preclinical
- Lead developer
- Christian-Albrechts-Universität zu Kiel
- Modality
- Bacterial Toxin Conjugates → Immunotoxins → Antibody Conjugates → Antibody-Based Therapeutics, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
HM1.24-ETA' is an experimental, preclinical recombinant single-chain immunotoxin designed for the treatment of CD317-expressing malignancies, including multiple myeloma, plasma cell leukemia, and glioblastoma. It is a biologic fusion protein consisting of a CD317-specific (HM1.24) single-chain variable fragment (scFv) antibody genetically fused to ETA', a truncated form of Pseudomonas aeruginosa exotoxin A that lacks the cell-binding domain I. HM1.24-ETA' targets CD317 (bone marrow stromal antigen 2 / BST2), which is overexpressed on malignant plasma cells and glioma cells. Upon binding, the immunotoxin is internalized, and the ETA' payload inhibits protein synthesis, leading to cell death via apoptosis. The recombinant protein is expressed in Escherichia coli. HM1.24-ETA' was developed by researchers at Kiel University and has been evaluated in collaboration with the University of Zurich.
- Other names
- HM1.24-ETAHM-1.24-ETAHM 1.24-ETAHM1.24-ETA primeHM-1.24-ETA primeHM 1.24-ETA prime
02
Targets
BST2 (Bone marrow stromal cell antigen 2)
Beyond the preview
Go deeper on HM1.24-ETA'.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HM1.24-ETA'.